Distamycin A (Dista A, Figure 1 ) is an antiviral antibiotic originally isolated from cultures of Streptomyces distallycus (Di Marco et al., 1962) , whose structure was characterised in our laboratories (Arcamone et al., 1964) . In experimental models, Dista A has shown only minimal cytotoxic and antitumour activity whereas it revealed a potent antiviral activity especially against Herpes simplex (Casazza et al., 1965) . Dista A has been demonstrated to inhibit DNApolymerase, secondary to a strong and selective affinity for T:A-rich sequences of B DNA (Zimmer & Wahnert, 1986) .
In the aim of obtaining anticancer agents with potentially novel molecular target(s) and mechanism(s) of action, a number of Dista A derivatives bearing different alkylating reactive moieties were synthesised. The synthesis, DNAbinding properties and preliminary information on the biological activity of a number of selected derivatives have been published (Arcamone et al., 1989) .
In this report we describe results obtained in the characterisation of the antineoplastic activity in experimental models of FCE 24517 (Figure 1) Cell cultures L1210 and L1210/L-PAM murine leukaemia cells were routinely derived from leukaemia-bearing mice and maintained in RPMI 1640 medium (Gibco 074-1800) supplemented with 0.01 and 0.05 mM P-mercaptoethanol, respectively. LoVo (Drewinko et al., 1976) and LoVo/DX (Grandi et al., 1986) human colon carcinoma cells were maintained in Ham's F12 medium (Gibco 074-1700). All culture mediums were supplemented with 10% foetal calf serum (Flow), 1% of a glutamine solution (200 mM), penicillin (100 IU ml-1), streptomycin (100 tg ml -') and kanamycin (1001tigml-'). Cells were maintained at 37C in humidified atmosphere of 5% CO2 and passaged twice weekly.
Evaluation of in vitro cytotoxicity A colony inhibition test was employed in the case of LoVo and LoVo/DX cells: a total of 600 cells in 2 ml medium were seeded in 60 mm tissue culture dishes (Falcon) 24 h before treatment; after 4 h exposure to drugs, dishes were washed with saline and fresh growth medium added. Surviving col- (Di Marco et al., 1972) . The P02 murine pancreatic carcinoma (Corbett et al., 1984) , and the MXT murine fibrosarcoma (Zaccheo et al., 1986) were transplanted s.c. in compatible B6D2F1 mice, whereas the murine colon 38 tumour was transplanted s.c. in syngeneic C57BL/6 mice, using in all cases inocula of 15-20 mg of tumor brei. The human small cell lung carcinoma N592, A549 lung adenocarcinoma (both originally obtained from the ATCC), melanoma M14 (Natali et al., 1983) , and LoVo colon carcinoma (Drewinko et al., 1976) were transplanted s.c. in athymic mice using 15-20mg of tumor brei.
In experiments in leukaemia models, drug activity was evaluated in terms of per cent increase in median survival time in comparison to untreated controls (T/C %). In experiments with solid tumours, primary tumour growth was assessed by caliper measurement, and tumour weight was estimated (Geran et al., 1972) . Toxicity was evaluated on the basis of gross autopsy findings, as well as on the basis of reduction in survival time below that of untreated controls.
Results
In vitro cytotoxic activity Table I shows data obtained testing the in vitro antiproliferative activity of FCE 24517 on parental L1210 and LoVo cells and their L-PAM and DX-resistant sublines. On both parental L1210 and LoVo cells, FCE 24517 was clearly cytotoxic, with IC50 values in the range of 0.14 to 0.6 lag ml -, whereas the parent compound Dista A was only active at higher concentrations. On L12lO/L-PAM cells the cytotoxic activity of FCE 24517 was comparable to that seen on parental cells, thus indicating a lack of cross-resistance with classical alkylating agents such as L-PAM. Conversely, cross-resistance was observed on LoVo/DX, a subline exhibiting the 'classical multidrug resistance' (mdr) phenotype (Ballinari et al., 1988 Representative data on the response of different human tumour xenografts to FCE 24517 are shown in Table IV . It can be seen that at the dose of 1 mg kg-' i.v. q4dx3, this compound was active against the N592 human small cell lung carcinoma and M14 melanoma, producing tumour inhibition values of 95% and 86%, respectively. Lower activity was seen when FCE 24517 was tested against the s.c. transplanted LoVo human colon adenocarcinoma and A549 human lung adenocarcinoma lines, as revealed by tumour growth inhibitions in the 40-50% range.
Discussion
The results presented in this report demonstrate that FCE 24517 possesses a clear and broad-spectrum antineoplastic activity in experimental conditions, and thus that this compound, a derivative of the antiviral agent Dista A bearing at the N-terminal an alkylating benzoyl mustard moiety, represents a novel chemical class of antitumoural agents.
The insertion of an alkylating moiety on the Dista A skeleton confers to this molecule a potent antiproliferative activity. In fact, FCE 24517 is significantly more cytotoxic than its parent compound not only on L1210 and LoVo cells (Table I) but also on several other murine and human cell lines so far investigated (data not shown). Notwithstanding its alkylating appendage, FCE 24517 was observed to have an equivalent cytotoxic activity on parental and L-PAMresistant L1210 cells, this lack of cross-resistance being confirmed in vivo on the same cell lines. Conversely, FCE 24517 was cross-resistant on LoVo/DX cells, a subline exhibiting the classical mdr phenotype.
FCE 24517 showed a clear antineoplastic activity in vivo against a variety of experimental tumours of both murine and human origin, although the best activities were obtained in most cases near the maximum tolerated doses, and the degree of therapeutic effectiveness observed varied in different models. Treatment with FCE 24517 was in fact effective against the murine MTV mammary, P02 pancreatic and Colon 38 carcinomas, M5076 reticulosarcoma and MXT fibrosarcoma as well as on xenografts of the human M14 melanoma and N592 small cell lung carcinoma as indicated by over 70-80% inhibition of tumour growth. Lower effectiveness was observed on the murine Lewis lung carcinoma, human A549 lung adenocarcinoma and LoVo colon adenocarcinoma with primary tumour growth inhibition in the 40-50% range. It should however be noted that no systematic attempt was made in this study to identify the optimal in vivo treatment schedules for improving the therapeutic index or enlarging the spectrum of activity. FCE 24517 was additionally active in the murine Gross leukaemia model and, if given i.p., against the L1210 leukaemia and its L-PAM-resistant subline. In contrast, systemic treatment with this agent was associated with only marginal activity against i.v.-transplanted L1210 and P388 leukaemias despite the use of doses active in the Gross leukaemia model.
The basis for this low antileukaemic effectiveness remains hypothetical and more than one determinant may be involved. In this connection, it is also worth noting that preliminary results indicate marginal activity in the P388 and L1210 models also employing repeated FCE 24517 administrations at doses and schedules clearly active in solid tumours (data not shown), a finding unexpected in view of the well known fact that these leukaemias have shown greater responsiveness then solid experimental neoplasms to the majority of known cancer chemotherapeutics (Staquet et aT.I.%: percentage of tumour growth inhibition, determined 1 week after the last treatment.
al. Grindey, 1990) . Although data so far available would appear to suggest this molecule possesses an unusual pattern of antineoplastic activity with limited antileukaemic effectiveness and clear, broad spectrum efficacy in experimental solid tumours, results in other leukaemia-lymphoma models are however needed before a more firm conclusion on this differential activity is advanced. Should such confirmations be obtained, the indication that FCE 24517 represents the lead of a novel class of cancer chemotherapeutics would be reinforced. The cellular and molecular mechanisms at the basis of the antitumour activity of FCE 24517 are only partially resolved and a matter of active ongoing investigation. In a recent report (Broggini et al., 1991) , evidence is presented that in cultured L1210 cells this compound does not act as an inhibitor of DNA, RNA and protein synthesis, nor as an antimitotic agent, and to block cells in G2. In the same cell type, exposure to cytocidal concentrations of FCE 24517 was not associated with DNA strand breaks, interstrand crosslinks or DNA-protein cross-links. Dista A has been shown to bind selectively to T:A-rich sequences in B DNA and it has been reported that binding of this molecule to DNA minor groove induces conformational changes in neighbouring DNA which may affect protein-DNA interactions (Kopka et al., 1985) . Dista A has also recently been observed to inhibit the binding of selected regulatory proteins to their T:A-rich DNA sequences (Broggini et al., 1989) . However FCE 24517 was found to be quantitatively comparable to Dista A in both DNA binding in vitro and in inhibiting the binding of regulatory proteins to T:A-rich regions, and both compounds appear to have similar cellular uptake and retention characteristics (Broggini et al., 1991) . Since Dista A is essentially inactive as an antitumour agent in vitro and in vivo even at concentrations 100 times higher than those effective for the derivative, it would appear that the alkylating benzoyl mustard absent in Dista A and present in FCE 24517 is essential in imparting an antiproliferative capacity to the latter. Alkylation of DNA by FCE 24517 is however weak, and in contrast to known nitrogen mustards, this compound does not induce alkylation at guanine N7 but at selected adenines (Broggini et al., 1991) . The exact molecular mechanisms of this molecule are however still a matter of speculation also in consideration of the finding that this compound has additionally been found to display a very potent inhibitory activity for DNA ligase in conditions not affecting DNA polymerases (Montecucco et al., 1991) . In view of its mode of action that on the basis of available evidence seems different from known cytototoxic agents, and its broad spectrum of activity in experimental conditions, FCE 24517 appears to be an interesting candidate for clinical evaluation and phase I studies are already ongoing.
